Various forms of blood cancer exist—all of which are grouped together under the term leukemia. One common form of leukemia is acute myeloid leukemia (AML), characterized by a degradation of early blood cell precursors, ...
Dec 18, 2024
0
2
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median follow-up of 6.1 years, ...
Dec 11, 2024
0
0
Patients with acute myeloid leukemia who have lower education levels and lower income are less likely to receive an allogeneic hematopoietic stem cell transplant for acute myeloid. However, if they can access the treatment, ...
Dec 9, 2024
0
0
A novel, fixed-duration drug combination—consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 inhibitor (venetoclax), with or without a third blood cancer drug—shows deep and durable responses ...
Dec 9, 2024
0
0
Just days before his fourth birthday, Santiago was diagnosed with B-cell acute lymphoblastic leukemia (B-ALL), the most common cancer in children. He began chemotherapy the next day, and the outlook was promising—disease-free ...
Dec 7, 2024
0
43
Researchers at University of California San Diego School of Medicine and their colleagues have developed the first comprehensive map of the dramatic changes that take place in the blood system over the course of the human ...
Dec 6, 2024
0
23
Adding a new drug to standard care for stem cell transplant recipients may reduce a life-threatening side effect, according to an early-stage clinical trial conducted at Washington University School of Medicine in St. Louis.
Dec 5, 2024
0
0
A new method can improve treatment for patients with chronic myeloid leukemia by predicting which medication will be most effective. The method also works for other forms of cancer where resistance may develop. A step is ...
Dec 4, 2024
0
37
Researchers at the Icahn School of Medicine at Mount Sinai have discovered how genetics can affect the success of venetoclax, a treatment for multiple myeloma, a rare type of blood cancer. Their study, "Predictors of Response ...
Nov 29, 2024
0
6
Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene autoleucel (obe-cel), experienced ...
Nov 28, 2024
0
33
